Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Mara Aspinall, Kenneth Buechler, and more

Mara Aspinall 

Mara Aspinall was named executive chairman of the Lifeprint Group's board of directors. Aspinall currently is CEO of the consulting firm Health Catalysts. She was previously the president and CEO of Roche's Ventana Medical Systems and spent more than a decade at Genzyme, where she held various leadership roles, including president of Genzyme Genetics and Genzyme Pharmaceuticals.

The appointment was announced by GenePeeks, a firm held by Lifeprint, which uses next-generation sequencing to help parents assess the risk of inherited diseases for their future children.  

Kenneth Buechler, Dirk van den Boom

Sequenom's board of directors has elected Kenneth Buechler its chairman, effective April 1. He succeeds Harry Hixson, who is retiring from the position after 11 years. Also, Dirk van den Boom was elected as a director, effective April 1.

Buechler has been on Sequenom's board since late 2009 and was previously president and CSO of Biosite, which he co-founded. Before that he was a senior research scientist for the diagnostics R&D group at Hybritech. 

Van den Boom is currently executive vice president and chief scientific and strategy officer at Sequenom. He will serve on the board's science committee.

Matthew Posard

Matthew Posard has joined Trovagene as executive vice president and chief commercial officer. He joins the company from Illumina where he was senior vice president and general manager for the company's new and emerging marketing opportunities business. He also has served as the general manager of Illumina's translational and consumer genomics business and vice president of global marketing. Prior to Illumina, he had leadership roles in sales and marketing at Biosite and worked in strategic and product manufacturing at Gen-Probe, now part of Hologic.


Daniel Swan

Daniel Swan has joined The Genome Analysis Center (TGAC) as head of the platform and pipelines group, where he will be responsible for the research institute's suite of advanced genome analysis facilities.

Previously, Swan headed NGS analysis at Oxford Gene Technology and was responsible for developing NGS products and services for academic, commercial, and clinical research customers. He also has worked at the National Environmental Research Council's environmental bioinformatics center, and he ran Newcastle University's bioinformatics core facility.

Swan trained as a vertebrate developmental biologist at Imperial College London and Edinburgh University before transitioning into bioinformatics with a post at Barts and the London Genome Center.  

For more recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.